Lysine methylation-mediated SMYD2 degradation by casticin sensitizes non-small-cell lung cancer cells to osimertinib therapy
sciencedirect.com/science/article/abs/pii/S00...Posted Dec 1, 2025, 4:12 AM UTC
20
sciencedirect.com
Loading comments…
Posted Dec 1, 2025, 4:12 AM UTC